In the study of Park et al. involving 125 NSCLC patients receiving PD-1/PD-L1 inhibitor treatment, found that the low IL-6 group (<13.1 pg/mL) had significantly higher ORR and disease control rate (DCR) compared to the high IL-6 group (Kang et al., 2020). Here, PDCD1 is linked to non-small cell lung carcinoma.